|Bid||273.85 x 1400|
|Ask||274.11 x 1100|
|Day's Range||268.40 - 274.26|
|52 Week Range||244.08 - 459.75|
|Beta (3Y Monthly)||1.26|
|PE Ratio (TTM)||56.97|
|Earnings Date||May 2, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||414.56|
Abiomed (ABMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New research adds to 12 years of real-world data and FDA studies demonstrating the use of Abiomed's Impella heart pumps during high-risk PCI enables skilled interventional cardiologists to achieve more complete revascularization, improved ejection fraction and quality of life, and a reduction in post-discharge adverse events.
While ABIOMED, Inc. (NASDAQ:ABMD) shareholders are probably generally happy, the stock hasn't had particularly good run recently, with the share price falling 23% in the last quarter. But that does not change the realty t...
On CNBC's "Mad Money Lightning Round," Jim Cramer said Signet Jewelers Ltd. (NYSE: SIG ) needs to find its calling. He was not impressed by the last quarter and he wants to wait. Funko Inc ...
Abiomed (ABMD) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Company will host a conference call to discuss the results on Thursday, May 2, 2019, at 8:00 a.m. EDT. Michael R. Minogue, Chairman, President and Chief Executive Officer and Todd Trapp, Chief Financial Officer, will host the conference call.
The Zacks Analyst Blog Highlights: Heidrick & Struggles International, ABIOMED, SeaWorld Entertainment, Darden Restaurants and AAON
Medical technology stocks hit record highs last year and are spiking in 2019. Four of the fastest growing among them have tacked on double-digit earnings growth for several years.
Three years ago this week, Abiomed's Impella heart pump received its FDA PMA approval for AMI cardiogenic shock. At the time of Impella’s FDA PMA approval, the cardiogenic shock survival rate to explant in the Impella Quality Assurance Database was 51% in the United States1.
Abiomed (ABMD) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! Investors looking for stocks with high market liquidity and zero debt on the balance sheet should consider ABIOMED, Inc. (N...
Despite cutthroat competition in the niche markets, ABIOMED (ABMD) seems to be well-positioned for growth on strong guidance and solid product portfolio.